11,950 Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 4.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,022 shares of the medical research company’s stock after buying an additional 11,950 shares during the period. Amgen comprises approximately 1.2% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 20th largest holding. Ferguson Wellman Capital Management Inc.’s holdings in Amgen were worth $103,614,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. State Street Corp lifted its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. Bank of America Corp DE acquired a new stake in shares of Amgen during the 2nd quarter worth about $1,831,903,000. Capital World Investors increased its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. Wellington Management Group LLP boosted its position in Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after buying an additional 2,514,254 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMGN. UBS Group reiterated a “buy” rating and issued a $430.00 target price on shares of Amgen in a research note on Thursday, September 17th. Wells Fargo & Company raised their price target on Amgen from $400.00 to $435.00 and gave the company an “equal weight” rating in a report on Friday, September 4th. Mizuho boosted their price objective on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Piper Sandler increased their price objective on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $385.25.

Insider Activity at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last three months. 0.85% of the stock is owned by insiders.

Amgen Trading Up 0.1%

Shares of AMGN stock traded up $0.36 during trading hours on Monday, reaching $403.40. The company had a trading volume of 927,812 shares, compared to its average volume of 2,753,245. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm has a market cap of $218.09 billion, a price-to-earnings ratio of 25.07, a P/E/G ratio of 2.91 and a beta of 0.41. The company has a 50 day moving average of $410.72 and a 200 day moving average of $370.36.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the prior year, the company posted $6.02 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s dividend payout ratio is 62.65%.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.